Thomas W. Doebber

TL;DR: It is concluded that MK-0767 is a potent dual PPARα/γ agonist with robust insulin sensitizing and hypolipidemic activities.

TL;DR: As PAF was being characterized as a highly potent lipid mediator of inflammation and anaphylaxis, its unusual structure stimulated considerable interest in the investigation of various structural analogs, initially to define the structure requirement for its biological actions, and later to explore the possibility of dissociating its cardiovascular, pulmonary, and renal activities.

TL;DR: The moderate PPARalpha activity of 12d not only contributed to the agent's ability to manage lipid profiles but also appears to have potentiated its PPARgamma efficacy in lowering glucose levels in preclinical diabetic animal models.

TL;DR: A structure–activity relationship study of these compounds led to the identification of potent, orally active PPAR dual α/γ agonists, and compound 12 was selected for further profiling.

TL;DR: An enantioselective synthesis of MK 287 (L-680,573), a member of a family of trans-,5-diaryltetrahydrofurans, and its biological activity are described in this article.